Isis, Lilly Expand Collaboration Into Cancer Drugs

isis-pharmaIsis Pharmaceuticals Inc. and and Co. have expanded their collaboration to develop cancer drugs based on a technology known as antisense.

Isis, a small biotechnology company based in Carlsbad, California, and drug giant Lilly, based in Indianapolis, said they had formed a two-year collaboration to discover drugs associated with specific genes that the companies believe are associated with cancer.

Last August, Lilly agreed to invest more than $200 million in an alliance with Isis.

The agreement included Lilly taking a 9 percent stake in Isis and rights to Isis’s experimental lung-cancer drug.

The companies agreed to jointly develop drugs in the fields of inflammatory and metabolic diseases.

The expanded alliance will focus on a number of antisense compounds currently in the preclinical stage of development.


Dragon Pharma operates four separate pharmacy businesses from its location in Europe. They offer in-store and mail order steroids: Purchase Sustanon 350.